GlassScriptPhysician profile
Fallon M Kapatais
NPI 1477811925
$3,793.07
in general payments reported to CMS, 2019-2025
33 companies · $890 in 2025
The $890 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $135 · 2021: $152 · 2022: $53.92 · 2023: $837 · 2024: $1,139 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,865.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.87 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $582.02 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $337.80 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $241.34 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $215.79 | 2019-2025 | Repatha, Otezla, Otezla |
| Neurocrine Biosciences, INC. | $192.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $183.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.48 | 2023-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $165.41 | 2023-2025 | |
| Pfizer INC. | $142.54 | 2022-2025 | |
| Penumbra, INC. | $124.99 | 2023 | Indigo System |
| Dexcom, INC. | $100.13 | 2021-2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $79.63 | 2019 | |
| Merck Sharp & Dohme LLC | $77.75 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $51.28 | 2024-2025 | Trelegy Ellipta, Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.31 | 2024-2025 | Jardiance |
| Esperion Therapeutics, INC. | $37.61 | 2023-2025 | Nexletol |
| Exact Sciences Corporation | $35.41 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $35.39 | 2023 | |
| Amneal Pharmaceuticals LLC | $34.09 | 2023-2024 | Unithroid |
| Axsome Therapeutics, INC. | $32.20 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $31.41 | 2024 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $25.28 | 2022 | |
| Medicomp INC | $21.64 | 2024 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $19.96 | 2024 | Injectafer |
| Tactile Systems Technology INC | $19.93 | 2024 | Flexitouch Plus, Entre Plus |
| Si-Bone, INC. | $18.87 | 2023 | |
| Seqirus USA INC | $17.95 | 2024 | Flucelvax, Fluad |
| Kaleo, INC. | $16.15 | 2023 | Auvi-Q |
| Medtronic, INC. | $15.30 | 2023 | Minimed 780g |
| Shield Therapeutics INC | $15.22 | 2024 | |
| Dynavax Technologies Corporation | $14.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.87 | 2023 | Livalo, Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fallon Kapatais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.